title: Multitargeted therapies for multiple myeloma.
abstract: Multiple myeloma (MM) comprises 1% of all malignancies and 10% of all hematological malignancies. MM is a malignancy of plasma cells in the bone marrow where complex and dynamic interactions with the bone marrow microenvironment lead to tumor progression, skeletal destruction and angiogenesis. Despite the discovery of several novel treatments against MM, including the proteasome inhibitor bortezomib, it is considered to be an incurable disease with an average 4-5 years overall survival.
authors.affiliation: Department of Oncology-Pathology, Cancer Centre Karolinska, Karolinska Institutet, Stockholm, Sweden.
authors.forename: Pedram
authors.initials: P
authors.lastname: Kharaziha
authors.forename: Sophia
authors.initials: S
authors.lastname: Ceder
authors.forename: Claire
authors.initials: C
authors.lastname: Sanchez
authors.forename: Theocharis
authors.initials: T
authors.lastname: Panaretakis
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D006801:Humans; D051379:Mice; D008954:Models, Biological; D058990:Molecular Targeted Therapy; D009101:Multiple Myeloma / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D000077157:Sorafenib
chemical_list: D010671:Phenylurea Compounds; D019253:Proto-Oncogene Proteins c-bcl-2; D009536:Niacinamide; D000077157:Sorafenib